{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T22:53:41Z","timestamp":1772751221784,"version":"3.50.1"},"reference-count":50,"publisher":"Informa UK Limited","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2010,7,31]]},"DOI":"10.2217\/fon.10.74","type":"journal-article","created":{"date-parts":[[2010,7,13]],"date-time":"2010-07-13T11:08:22Z","timestamp":1279019302000},"page":"1073-1084","source":"Crossref","is-referenced-by-count":31,"title":["Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Cancer"],"prefix":"10.1080","volume":"6","author":[{"given":"Rudolph M","family":"Navari","sequence":"first","affiliation":[{"name":"Indiana University School of Medicine South Bend, 1234 North Notre Dame Avenue, South Bend, IN46617\u20131404, USA."},{"name":"Harper Cancer Institute, South Bend, IN46617, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2010,7,13]]},"reference":[{"key":"e_1_3_2_3_1_1","doi-asserted-by":"publisher","DOI":"10.3816\/SCT.2005.n.011"},{"key":"e_1_3_2_3_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-006-0173-z"},{"key":"e_1_3_2_3_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11408"},{"key":"e_1_3_2_3_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20230"},{"key":"e_1_3_2_3_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-004-0718-y"},{"key":"e_1_3_2_3_6_1","doi-asserted-by":"publisher","DOI":"10.1517\/14728214.11.1.137"},{"key":"e_1_3_2_3_7_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200969050-00002"},{"key":"e_1_3_2_3_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-004-0700-8"},{"key":"e_1_3_2_3_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.022"},{"key":"e_1_3_2_3_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(05)70325-9"},{"key":"e_1_3_2_3_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-004-0651-0"},{"key":"e_1_3_2_3_12_1","first-page":"89","article-title":"Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting: two new agents.","volume":"1","author":"Navari RM","year":"2003","unstructured":"Navari RM : Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting: two new agents.J. Support. Oncol.1, 89\u2013103 (2003).","journal-title":"J. Support. Oncol."},{"key":"e_1_3_2_3_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.9591"},{"key":"e_1_3_2_3_14_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200059060-00008"},{"key":"e_1_3_2_3_15_1","first-page":"477","article-title":"Study on clinical effect of a continuous intravenous infusion of azasetron against nausea and vomiting induced by anticancer drugs including CDDP.","volume":"23","author":"Kimura E","year":"1996","unstructured":"Kimura E , NiimiE, WatanabeAet al.: Study on clinical effect of a continuous intravenous infusion of azasetron against nausea and vomiting induced by anticancer drugs including CDDP.Gan To Kagaku Ryoho.23, 477\u2013481 (1996).","journal-title":"Gan To Kagaku Ryoho."},{"key":"e_1_3_2_3_16_1","first-page":"1163","article-title":"Usefulness of ramosetron hydrochloride on nausea and vomiting in CMF or CEF therapy for breast cancer.","volume":"26","author":"Taguchi T","year":"1999","unstructured":"Taguchi T , TsukamotoF, WatanabeTet al.: Usefulness of ramosetron hydrochloride on nausea and vomiting in CMF or CEF therapy for breast cancer.Gan To Kagaku Ryoho.26, 1163\u20131170 (1999).","journal-title":"Gan To Kagaku Ryoho."},{"key":"e_1_3_2_3_17_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1C510"},{"key":"e_1_3_2_3_18_1","unstructured":"WHO Drug Information. 20. No. 3 (2006)."},{"key":"e_1_3_2_3_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11817"},{"key":"e_1_3_2_3_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg417"},{"key":"e_1_3_2_3_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh047"},{"key":"e_1_3_2_3_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl137"},{"key":"e_1_3_2_3_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70313-9"},{"key":"e_1_3_2_3_24_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.90952.2008"},{"key":"e_1_3_2_3_25_1","unstructured":"Aloxi \u00ae (palonosetron HCl) injection prescribing information. Eisai Inc. Woodcliffe Lake NJ USA (2008)."},{"key":"e_1_3_2_3_26_1","first-page":"6254S","article-title":"Palonosetron, a new 5-HT3 antagonist does not alter anti-tumor efficacy of various chemotherapeutics in tumor bearing mice.","volume":"9","author":"Cantoreggi S","year":"2003","unstructured":"Cantoreggi S , ParisiS, Van LaarEet al.: Palonosetron, a new 5-HT3 antagonist does not alter anti-tumor efficacy of various chemotherapeutics in tumor bearing mice.Clin. Cancer Res.9, 6254S (2003) (Abstract).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_2_3_27_1","first-page":"35","article-title":"Measuring the maintenance of daily life activities using the Fuctional Living Index\u2013Emesis (FLIE) in patients receiving moderately emetogenic chemotherapy.","volume":"4","author":"Decker GM","year":"2006","unstructured":"Decker GM , DeMeyerES, KiskoDL: Measuring the maintenance of daily life activities using the Fuctional Living Index\u2013Emesis (FLIE) in patients receiving moderately emetogenic chemotherapy.J. Support. Oncol.4, 35\u201341 (2006).","journal-title":"J. Support. Oncol."},{"key":"e_1_3_2_3_28_1","unstructured":"Cartmell AD FergusonS YanagiharaRet al.: Protection against chemotherapy-induced nausea and vomiting is maintained over multiple cycles of moderately or highly emetogenic chemotherapy by palonosetron a potent 5-HT 3 receptor antagonist.Proc. Am. Soc. Clin. Oncol.756 (2003) (Abstract 3041)."},{"key":"e_1_3_2_3_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-008-0503-4"},{"key":"e_1_3_2_3_30_1","doi-asserted-by":"publisher","DOI":"10.1213\/ane.0b013e318172fa74"},{"key":"e_1_3_2_3_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2009.10.002"},{"key":"e_1_3_2_3_32_1","first-page":"403","article-title":"Palonosetron plus aprepitant and dexamethasone is a highly effective combination to prevent chemotherapy induced nausea and vomiting after emetogenic chemotherapy.","volume":"4","author":"Grote T","year":"2006","unstructured":"Grote T , HajdenbergJ, CartmellADet al.: Palonosetron plus aprepitant and dexamethasone is a highly effective combination to prevent chemotherapy induced nausea and vomiting after emetogenic chemotherapy.J. Support. Oncol.4, 403\u2013408 (2006).","journal-title":"J. Support. Oncol."},{"key":"e_1_3_2_3_33_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006291625"},{"key":"e_1_3_2_3_34_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270004264641"},{"key":"e_1_3_2_3_35_1","first-page":"369","article-title":"Palonosetron improves prevention of chemotherapy induced nausea and vomiting in elderly patients.","volume":"3","author":"Aapro MS","year":"2005","unstructured":"Aapro MS , MacciocchiA, GridelliC: Palonosetron improves prevention of chemotherapy induced nausea and vomiting in elderly patients.J. Support. Oncol.3, 369\u2013374 (2005).","journal-title":"J. Support. Oncol."},{"key":"e_1_3_2_3_36_1","first-page":"467","article-title":"Infusion of palonosetron plus dexamethasone is effective and safe for the prevention of chemotherapy-induced nausea and vomiting.","volume":"4","author":"Hajdenberg J","year":"2006","unstructured":"Hajdenberg J , GroteT, YeeLet al.: Infusion of palonosetron plus dexamethasone is effective and safe for the prevention of chemotherapy-induced nausea and vomiting.J. Support. Oncol.4, 467\u2013471 (2006).","journal-title":"J. Support. Oncol."},{"key":"e_1_3_2_3_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-007-0248-5"},{"key":"e_1_3_2_3_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-004-0755-6"},{"key":"e_1_3_2_3_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20001001)89:7<1634::AID-CNCR29>3.0.CO;2-V"},{"key":"e_1_3_2_3_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2009.07.071"},{"key":"e_1_3_2_3_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-007-0255-6"},{"key":"e_1_3_2_3_42_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2007.0007"},{"key":"e_1_3_2_3_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-008-0510-5"},{"issue":"413","key":"e_1_3_2_3_44_1","first-page":"A04","article-title":"Post-marketing experience of palonosetron confirms a favorable benefit\/risk profile.","volume":"13","author":"Bissoli F","year":"2005","unstructured":"Bissoli F , McGiugganM, BertazzoliM: Post-marketing experience of palonosetron confirms a favorable benefit\/risk profile.Support. Care Cancer13(413), A04 (2005).","journal-title":"Support. Care Cancer"},{"key":"e_1_3_2_3_45_1","first-page":"510B","article-title":"Safety profile of palonosetron, a pharmacologically distinct 5-HT3 receptor antagonist recently approved for acute and delayed chemotherapy induced nausea.","volume":"102","author":"Hajdenberg J","year":"2003","unstructured":"Hajdenberg J : Safety profile of palonosetron, a pharmacologically distinct 5-HT3 receptor antagonist recently approved for acute and delayed chemotherapy induced nausea.Blood102, 510B (2003) (Abstract 5770).","journal-title":"Blood"},{"key":"e_1_3_2_3_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6349(07)70675-4"},{"key":"e_1_3_2_3_47_1","first-page":"15S","article-title":"Is there a preferred dose of palonosetron? Results of an abstracted data meta-analysis of all eight randomized double-blind studies and the impact on guideline considerations.","volume":"27","author":"Raftopoulas H","year":"2009","unstructured":"Raftopoulas H , BriaE, GrallaRet al.: Is there a preferred dose of palonosetron? Results of an abstracted data meta-analysis of all eight randomized double-blind studies and the impact on guideline considerations.J. Clin. Oncol.27, 15S (2009) (Abstract 9636).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_4_2_1","unstructured":"ASCO patient guide: preventing nausea and vomiting caused by cancer treatment (2006) www.plwc.org (Accessed August 2009)"},{"key":"e_1_3_2_4_3_1","unstructured":"The NCCN clinical practice guidelines in oncology (2009) www.nccn.org (Accessed August 2009)"},{"key":"e_1_3_2_4_4_1","unstructured":"Multinational Association of Supportive Care in Cancer antiemetic guidelines (2009) www.mascc.org (Accessed August 2009)"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon.10.74","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:42:25Z","timestamp":1719124945000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon.10.74"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,13]]},"references-count":50,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2010,7,31]]}},"alternative-id":["10.2217\/fon.10.74"],"URL":"https:\/\/doi.org\/10.2217\/fon.10.74","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,13]]}}}